Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Transplantation. 2022 Jan 1;106(1):60–71. doi: 10.1097/TP.0000000000003754

Figure 6: DGF prevention with rhC1INH delays antibody-mediated rejection.

Figure 6:

Kaplan-Meier survival analysis of (a) Vehicle-treated recipients (n=5) averaged 44.7 days before AMR diagnosis (A), while rhC1INH-treated recipients (n=8) averaged 65.3 days (p=0.226). Two animals in the vehicle group and 3 in the rhC1INH group were death censored. (b) Recipients who developed DGF (n=5) vs recipients without DGF (n=8). Significance calculated with log-rank test (p=0.008). Statistics: Log-rank test was used to compare groups.